Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kymera Therapeutics (KYMR) Return on Equity (2020 - 2025)

Historic Return on Equity for Kymera Therapeutics (KYMR) over the last 6 years, with Q3 2025 value amounting to 0.35%.

  • Kymera Therapeutics' Return on Equity fell 900.0% to 0.35% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.35%, marking a year-over-year decrease of 900.0%. This contributed to the annual value of 0.43% for FY2024, which is 500.0% down from last year.
  • As of Q3 2025, Kymera Therapeutics' Return on Equity stood at 0.35%, which was down 900.0% from 0.36% recorded in Q2 2025.
  • Kymera Therapeutics' 5-year Return on Equity high stood at 0.17% for Q1 2021, and its period low was 0.45% during Q3 2023.
  • For the 5-year period, Kymera Therapeutics' Return on Equity averaged around 0.31%, with its median value being 0.32% (2024).
  • The largest annual percentage gain for Kymera Therapeutics' Return on Equity in the last 5 years was 2700bps (2021), contrasted with its biggest fall of -7100bps (2021).
  • Kymera Therapeutics' Return on Equity (Quarter) stood at 0.21% in 2021, then tumbled by -51bps to 0.32% in 2022, then plummeted by -30bps to 0.42% in 2023, then rose by 28bps to 0.3% in 2024, then decreased by -14bps to 0.35% in 2025.
  • Its Return on Equity stands at 0.35% for Q3 2025, versus 0.36% for Q2 2025 and 0.34% for Q1 2025.